Featured Intelligence

A single blood draw that can flag signals for dozens of different cancers sounds like exactly the kind of tool a careful, proactive approach to health should want. Several versions of this technology, broadly called multi-cancer early detection tests,

Biological age testing has existed as a consumer product for years, often sold with confident marketing and little independent evidence behind the number it produces. That changed somewhat this year. A series of large, peer-reviewed studies has now validated

CRISPR gene editing already has an approved medicine on the market, but getting it means a hospital stay, chemotherapy-style conditioning, and a process that can take months. That is the reality behind Casgevy, the first CRISPR-based therapy ever

When a genetic testing company goes bankrupt, its most valuable holding is not its lab equipment. It is the genetic profiles of everyone who ever sent in a saliva sample. That is exactly what played out with 23andMe, whose bankruptcy

For years, AI drug discovery has been judged mostly on promises: faster timelines, cheaper pipelines, smarter molecule design. This year, one of those promises finally reached a stage where it has to prove itself against real patients. Insilico Medicine'

A large independent review of fish oil supplements published this year offers a useful snapshot of where supplement quality verification actually stands. Consumer Reports tested more than fifty samples across twenty-one products for omega-3 content, rancidity, and a

The word bioprinting tends to conjure images of a printed kidney or lung ready for transplant, but the actual human clinical progress right now looks much smaller and more specific. A company called 3DBio Therapeutics ran the first FDA-authorized

Cord blood banking has quietly become a large, established industry: nearly five million units are stored worldwide, most in private family banks, with roughly a million more sitting in public registries available for matched patients. More than forty thousand cord

A new tariff structure aimed at pulling drug manufacturing back onto domestic soil hits a major compliance deadline this week. Fourteen major manufacturers, including Eli Lilly, AbbVie, AstraZeneca, Pfizer, and Merck, have pledged a combined figure well into the hundreds